SCHEMBL7350659

SCHEMBL7350659

CCCCCCOc1ccc(S(=O)(=O)N(CC(=O)NO)CC(C)C)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP3 P08254 10/20 1.00
MMP13 P45452 7/20 0.67
MMP2 P08253 6/20 0.67
MMP14 P50281 5/20 0.67
ADAMTS4 O75173 2/20 0.67
ADAMTS5 Q9UNA0 2/20 0.67
MMP1 P03956 7/20 0.62
MMP8 P22894 5/20 0.62
MMP9 P14780 4/20 0.62
ADAM17 P78536 1/20 0.60
CA1 P00915 1/20 0.59
CA2 P00918 1/20 0.59
CA9 Q16790 1/20 0.59
MMP7 P09237 2/20 0.55
MMP12 P39900 2/20 0.55
MEP1B Q16820 1/20 0.50
BMP1 P13497 1/20 0.49
MMP16 P51512 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7343349 1.00 MMP3 (1.00) MMP3MMP13MMP2MMP14ADAMTS4
SCHEMBL7341391 0.97 MMP3 (1.00) MMP3MMP13MMP2MMP14ADAMTS4
SCHEMBL26770275 0.92 MMP3 (0.91) MMP3MMP13MMP2MMP14ADAMTS4
SCHEMBL7346040 0.89 MMP3 (1.00) MMP3MMP13MMP2MMP14ADAMTS4
SCHEMBL26776730 0.88 MMP3 (0.83) MMP3MMP13MMP2MMP14ADAMTS4
SCHEMBL7348184 0.87 MMP3 (0.82) MMP3MMP13MMP2MMP14ADAMTS4
SCHEMBL7341425 0.87 MMP3 (1.00) MMP3MMP13MMP2MMP14ADAMTS4
SCHEMBL26776615 0.86 MMP3 (0.83) MMP3MMP13MMP2MMP14ADAMTS4
SCHEMBL26776715 0.86 MMP3 (0.83) MMP3MMP13MMP2MMP14ADAMTS4
SCHEMBL7345745 0.84 MMP3 (0.73) MMP3MMP13MMP2MMP14ADAMTS4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0766672-B1 ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS NOVARTIS AG (CH) 2000-10-04 EP disclosed
EP-0606046-B1 Arylsulfonamido-substituted hydroxamic acids CIBA GEIGY AG (CH) 1997-10-08 EP disclosed
US-5646167-A ADMINISTERED AS METALLOPROTEINASE INHIBITOR, ANTITUMOR OR ANTICARCINOGENIC AGENT CIBA-GEIGY CORPORATION (US) 1997-07-08 US disclosed
EP-0766672-A1 ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS Novartis AG (CH) 1997-04-09 EP disclosed
WO-1996040101-A1 CERTAIN ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS FOR THE TREATMENT OF CERTAIN TUMORS NOVARTIS AG (CH) 1996-12-19 WO disclosed
US-5552419-A METALLOPROTEINASE INHIBITORS CIBA-GEIGY CORPORATION (US) 1996-09-03 US disclosed
US-5506242-A METALLOELASTASE INHIBITOR; TREATS EMPHYSEMA CIBA-GEIGY CORPORATION (US) 1996-04-09 US disclosed
WO-1996000214-A1 ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS CIBA-GEIGY AG (CH) 1996-01-04 WO disclosed
US-5455258-A Useful as inhibitors of matrix-degrading metalloproteinase enzymes such as stromelysin and/or collegenase CIBA-GEIGY CORPORATION (US) 1995-10-03 US disclosed
EP-0606046-A1 Arylsulfonamido-substituted hydroxamic acids CIBA-GEIGY AG (CH) 1994-07-13 EP disclosed